MCK vs VCYT: fair value comparison
McKesson Corporation and Veracyte, Inc. · Updated 2026-09-06
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, MCK currently sits closer to the top of our discount ranking. VCYT carries the stronger quality grade.
| MCK | VCYT | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $907.99 | $44.85 |
| 12-month range | $734.82–$990.95 | $32.40–$59.85 |
| Sector rank | #80 of 113 Healthcare | #84 of 113 Healthcare |
| Quality grade | F | A |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: MCK fair value analysis · VCYT fair value analysis